These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 21914790)

  • 21. Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands.
    Carrión-Salip D; Panosa C; Menendez JA; Puig T; Oliveras G; Pandiella A; De Llorens R; Massaguer A
    Int J Oncol; 2012 Sep; 41(3):1128-38. PubMed ID: 22684500
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epidermal growth factor receptor inhibition strategies in oncology.
    Harari PM
    Endocr Relat Cancer; 2004 Dec; 11(4):689-708. PubMed ID: 15613446
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synergistic cytotoxicity of afatinib and cetuximab against EGFR T790M involves Rab11-dependent EGFR recycling.
    Watanuki Z; Kosai H; Osanai N; Ogama N; Mochizuki M; Tamai K; Yamaguchi K; Satoh K; Fukuhara T; Maemondo M; Ichinose M; Nukiwa T; Tanaka N
    Biochem Biophys Res Commun; 2014 Dec; 455(3-4):269-76. PubMed ID: 25446083
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective.
    Lacouture ME; Melosky BL
    Skin Therapy Lett; 2007; 12(6):1-5. PubMed ID: 17762902
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitors in cancer patients.
    Nardone B; Nicholson K; Newman M; Guitart J; Gerami P; Talarico N; Yang XJ; Rademaker A; West DP; Lacouture ME
    Clin Cancer Res; 2010 Sep; 16(17):4452-60. PubMed ID: 20732960
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Signaling effects of menadione: from tyrosine phosphatase inactivation to connexin phosphorylation.
    Abdelmohsen K; Patak P; Von Montfort C; Melchheier I; Sies H; Klotz LO
    Methods Enzymol; 2004; 378():258-72. PubMed ID: 15038974
    [No Abstract]   [Full Text] [Related]  

  • 27. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
    Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
    Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study.
    Ramalingam S; Forster J; Naret C; Evans T; Sulecki M; Lu H; Teegarden P; Weber MR; Belani CP
    J Thorac Oncol; 2008 Mar; 3(3):258-64. PubMed ID: 18317068
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Cutaneous side effects of EGFR inhibitors--appearance and management].
    Wollenberg A; Kroth J; Hauschild A; Dirschka T
    Dtsch Med Wochenschr; 2010 Jan; 135(4):149-54. PubMed ID: 20101558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evidence of epidermal growth factor receptor expression in uveal melanoma: inhibition of epidermal growth factor-mediated signalling by Gefitinib and Cetuximab triggered antibody-dependent cellular cytotoxicity.
    Amaro A; Mirisola V; Angelini G; Musso A; Tosetti F; Esposito AI; Perri P; Lanza F; Nasciuti F; Mosci C; Puzone R; Salvi S; Truini M; Poggi A; Pfeffer U
    Eur J Cancer; 2013 Oct; 49(15):3353-65. PubMed ID: 23849826
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
    Martinelli E; Troiani T; Morgillo F; Rodolico G; Vitagliano D; Morelli MP; Tuccillo C; Vecchione L; Capasso A; Orditura M; De Vita F; Eckhardt SG; Santoro M; Berrino L; Ciardiello F
    Clin Cancer Res; 2010 Oct; 16(20):4990-5001. PubMed ID: 20810384
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epidermal growth factor receptor inhibitor protects against abdominal aortic aneurysm in a mouse model.
    Obama T; Tsuji T; Kobayashi T; Fukuda Y; Takayanagi T; Taro Y; Kawai T; Forrester SJ; Elliott KJ; Choi E; Daugherty A; Rizzo V; Eguchi S
    Clin Sci (Lond); 2015 May; 128(9):559-65. PubMed ID: 25531554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments.
    Albanell J; Codony-Servat J; Rojo F; Del Campo JM; Sauleda S; Anido J; Raspall G; Giralt J; Roselló J; Nicholson RI; Mendelsohn J; Baselga J
    Cancer Res; 2001 Sep; 61(17):6500-10. PubMed ID: 11522647
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies.
    Segaert S; Tabernero J; Chosidow O; Dirschka T; Elsner J; Mancini L; Maughan T; Morere JF; Santoro A; Sobrero A; Van Cutsem E; Layton A
    J Dtsch Dermatol Ges; 2005 Aug; 3(8):599-606. PubMed ID: 16033478
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The epidermal growth factor receptor is a regulator of epidermal complement component expression and complement activation.
    Abu-Humaidan AH; Ananthoju N; Mohanty T; Sonesson A; Alberius P; Schmidtchen A; Garred P; Sørensen OE
    J Immunol; 2014 Apr; 192(7):3355-64. PubMed ID: 24591374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition.
    Albanell J; Rojo F; Averbuch S; Feyereislova A; Mascaro JM; Herbst R; LoRusso P; Rischin D; Sauleda S; Gee J; Nicholson RI; Baselga J
    J Clin Oncol; 2002 Jan; 20(1):110-24. PubMed ID: 11773160
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gefitinib-induced epidermal growth factor receptor-independent keratinocyte apoptosis is mediated by the JNK activation pathway.
    Lu PH; Kuo TC; Chang KC; Chang CH; Chu CY
    Br J Dermatol; 2011 Jan; 164(1):38-46. PubMed ID: 20846305
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EGFR inhibitors erlotinib and lapatinib ameliorate epidermal blistering in pemphigus vulgaris in a non-linear, V-shaped relationship.
    Sayar BS; Rüegg S; Schmidt E; Sibilia M; Siffert M; Suter MM; Galichet A; Müller EJ
    Exp Dermatol; 2014 Jan; 23(1):33-8. PubMed ID: 24279293
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Placebo-controlled phase II study of vitamin K3 cream for the treatment of cetuximab-induced rash.
    Eriksen JG; Kaalund I; Clemmensen O; Overgaard J; Pfeiffer P
    Support Care Cancer; 2017 Jul; 25(7):2179-2185. PubMed ID: 28197850
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diverse effects of combined radiotherapy and EGFR inhibition with antibodies or TK inhibitors on local tumour control and correlation with EGFR gene expression.
    Gurtner K; Deuse Y; Bütof R; Schaal K; Eicheler W; Oertel R; Grenman R; Thames H; Yaromina A; Baumann M; Krause M
    Radiother Oncol; 2011 Jun; 99(3):323-30. PubMed ID: 21665304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.